TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GT Biopharma ( (GTBP) ) has issued an update.
In September 2025, GT Biopharma‘s Series L Preferred Stockholders agreed to waive their redemption rights, as outlined in the Certificate of Designations. This waiver potentially impacts the company’s financial flexibility and stakeholder interests by altering the terms of preferred stock agreements.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
GT Biopharma operates in the biopharmaceutical industry, focusing on the development of innovative therapies for cancer treatment.
Average Trading Volume: 214,529
Technical Sentiment Signal: Sell
Current Market Cap: $2.85M
Learn more about GTBP stock on TipRanks’ Stock Analysis page.